Alerts will be sent to your verified email
Verify Email
PFIZER
|
Pfizer
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
4.8 % | 18.6 % | 6.1 % |
|
Financials
|
|||
|
5 yr Average ROE
|
19.03 % | 17.42 % | 17.74 % |
|
5yr average Equity Multiplier
|
1.25 | 1.99 | 1.76 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.91 | 0.51 |
|
5yr Avg Net Profit Margin
|
26.04 % | 9.65 % | 22.76 % |
|
Price to Book
|
5.98 | 28.2 | 7.5 |
|
P/E
|
27.4 | 113.16 | 55.76 |
|
5yr Avg Cash Conversion Cycle
|
21.86 Days | -6.33 Days | -54.68 Days |
|
Inventory Days
|
49.93 Days | 68.19 Days | 27.48 Days |
|
Days Receivable
|
29.1 Days | 35.81 Days | 54.07 Days |
|
Days Payable
|
77.28 Days | 187.52 Days | 148.48 Days |
|
5yr Average Interest Coverage Ratio
|
185.18 | 142.38 | 66.44 |
|
5yr Avg ROCE
|
23.84 % | 23.84 % | 18.34 % |
|
5yr Avg Operating Profit Margin
|
31.72 % | 14.57 % | 34.43 % |
|
5 yr average Debt to Equity
|
0.0 | 0.0 | 0.46 |
|
5yr CAGR Net Profit
|
76.68 % | 4.4 % | -0.19 % |
|
5yr Average Return on Assets
|
15.25 % | 8.92 % | 12.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
63.92 % | 75.0 % | 54.85 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 16.92 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 2.56 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
5.23 % | 3.91 % | 6.95 % |
|
Pfizer
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|